About Cylex, Incorporated
Cylex(TM) is a privately held global life sciences company that is the
leader in the development and manufacture of in vitro diagnostic products
intended to illuminate immunity. ImmuKnow is the in vitro diagnostic
utilized to detect cell-mediated immunity (CMI) in patient populations
undergoing immunosuppressive therapy, and is increasingly being adopted at
organ transplant centers throughout the US and abroad. The Company's
patented technology provides an innovative platform allowing clinical
researchers to simply and reproducibly measure immune cell function for the
development of new diagnostics, biomarkers, and companion assays. The
company is based in Columbia, MD.
(1) Tan HP, Donaldson J, Basu A, et al. 411 Living donor kidney
transplants using alemtuzumab pre-conditioning and tacrolimus
monotherapy: 5 year experience. Abstract no. 137 presented at the
American Transplant Congress, Toronto, Canada, May 30, 2008.
(2) Tan HP, Donaldson J, Basu A, et al. Rejection characteristics of 200
living donor kidney transplants using alemtuzumab induction and
tacrolimus monotherapy: 3 year follow-up. Abstract no. 221 presented
at the American Transplant Congress, Toronto, Canada, May 30, 2008.
|SOURCE Cylex, Incorporated|
Copyright©2008 PR Newswire.
All rights reserved